stoxline Quote Chart Rank Option Currency Glossary
ADMA Biologics, Inc. (ADMA)
9.21  0.15 (1.66%)    05-17 16:00
Open: 9.06
High: 9.31
Volume: 3,626,074
Pre. Close: 9.06
Low: 8.91
Market Cap: 2,135(M)
Technical analysis
2024-05-17 4:43:45 PM
Short term     
Mid term     
Targets 6-month :  10.89 1-year :  12.72
Resists First :  9.32 Second :  10.89
Pivot price 7.66
Supports First :  7.21 Second :  5.9
MAs MA(5) :  9.06 MA(20) :  7.36
MA(100) :  5.91 MA(250) :  4.63
MACD MACD :  0.7 Signal :  0.5
%K %D K(14,3) :  93 D(3) :  93.9
RSI RSI(14): 85.9
52-week High :  9.32 Low :  3.05
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ADMA ] has closed below upper band by 15.4%. Bollinger Bands are 355.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.32 - 9.38 9.38 - 9.42
Low: 8.77 - 8.84 8.84 - 8.9
Close: 9.11 - 9.21 9.21 - 9.3
Company Description

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Headline News

Fri, 17 May 2024
July 19th Options Now Available For ADMA Biologics - Nasdaq

Thu, 16 May 2024
ADMA Biologics, Inc. (NASDAQ:ADMA) Sees Large Growth in Short Interest - MarketBeat

Thu, 16 May 2024
ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by New York State Common Retirement Fund - Defense World

Thu, 16 May 2024 featured highlights ADMA Biologics, Northern Technologies, PlayAGS, Merchants Bank and Strategic ... - Yahoo Finance

Thu, 16 May 2024
ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Up 7.5% in April - Defense World

Tue, 14 May 2024
Russell Investments Group Ltd. Purchases 236,255 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 232 (M)
Shares Float 224 (M)
Held by Insiders 2.8 (%)
Held by Institutions 77.3 (%)
Shares Short 8,110 (K)
Shares Short P.Month 7,990 (K)
Stock Financials
EPS -0.13
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.6
Profit Margin -11 %
Operating Margin 19.2 %
Return on Assets (ttm) 4.5 %
Return on Equity (ttm) -19.7 %
Qtrly Rev. Growth 47.9 %
Gross Profit (p.s.) 0
Sales Per Share 1.11
EBITDA (p.s.) 0.14
Qtrly Earnings Growth 0 %
Operating Cash Flow 9 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -70.85
PEG Ratio 0
Price to Book value 15.34
Price to Sales 8.26
Price to Cash Flow 242.56
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android